GOSSAMER BIO, INC. Increase (Decrease) in Interest Payable, Net
GOSSAMER BIO, INC. (GOSS) reported Increase (Decrease) in Interest Payable, Net of -$411.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInterestPayableNet · last filed 2026-08-13
- GOSSAMER BIO, INC. increase (decrease) in interest payable, net for the quarter ending 2026-06-30 was -$2.91M.
- GOSSAMER BIO, INC. increase (decrease) in interest payable, net for the quarter ending 2026-03-31 was $2.50M, a 0.00% change year-over-year.
- GOSSAMER BIO, INC. increase (decrease) in interest payable, net for the quarter ending 2025-12-31 was -$2.50M.
- GOSSAMER BIO, INC. increase (decrease) in interest payable, net for the quarter ending 2025-09-30 was $2.50M, a 0.00% change year-over-year.
- GOSSAMER BIO, INC. increase (decrease) in interest payable, net for fiscal 2025 was $0.00.
- GOSSAMER BIO, INC. increase (decrease) in interest payable, net for fiscal 2024 was -$135.00K.
- GOSSAMER BIO, INC. increase (decrease) in interest payable, net for fiscal 2023 was -$97.00K.
- GOSSAMER BIO, INC. increase (decrease) in interest payable, net for fiscal 2022 was -$1.00K.
| Period end | Increase (Decrease) in Interest Payable, Net 3 month | Increase (Decrease) in Interest Payable, Net 6 month | Increase (Decrease) in Interest Payable, Net 9 month | Increase (Decrease) in Interest Payable, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$411.00K 10-Q · filed 2026-08-13 | -$2.91M derived: sum of 3 quarters · filed 2026-08-13 | -$411.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $2.50M 10-Q · filed 2026-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-05-15 | $2.50M derived: sum of 3 quarters · filed 2026-05-15 | $0.00 derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | -$2.50M derived: sum of 3 quarters · filed 2026-08-13 | $0.00 10-K · filed 2026-03-17 |
| 2025-09-30 | $2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2026-08-13 | $2.50M 10-Q · filed 2025-11-05 | $0.00 derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | -$2.50M derived: sum of 3 quarters · filed 2026-08-13 | $0.00 derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $2.50M 10-Q · filed 2026-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-05-15 | $2.50M derived: sum of 3 quarters · filed 2026-05-15 | -$104.00K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | -$2.60M derived: sum of 3 quarters · filed 2026-03-17 | -$135.00K 10-K · filed 2026-03-17 |
| 2024-09-30 | $2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$104.00K derived: sum of 2 quarters · filed 2025-11-05 | $2.37M 10-Q · filed 2025-11-05 | -$162.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | -$2.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$135.00K 10-Q · filed 2025-08-05 | -$2.66M derived: sum of 3 quarters · filed 2026-03-17 | -$189.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | $2.47M 10-Q · filed 2025-05-15 | -$58.00K derived: sum of 2 quarters · filed 2026-03-17 | $2.42M derived: sum of 3 quarters · filed 2026-03-17 | -$112.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | -$2.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$54.00K derived: sum of 2 quarters · filed 2026-03-17 | -$2.58M derived: sum of 3 quarters · filed 2026-03-17 | -$97.00K 10-K · filed 2026-03-17 |
| 2023-09-30 | $2.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$54.00K derived: sum of 2 quarters · filed 2024-11-07 | $2.43M 10-Q · filed 2024-11-07 | -$54.00K derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | -$2.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$43.00K 10-Q · filed 2024-08-12 | -$2.53M derived: sum of 3 quarters · filed 2025-03-13 | -$36.00K derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $2.48M 10-Q · filed 2024-05-07 | $0.00 derived: sum of 2 quarters · filed 2025-03-13 | $2.49M derived: sum of 3 quarters · filed 2025-03-13 | -$17.00K derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | -$2.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $7.00K derived: sum of 2 quarters · filed 2025-03-13 | -$2.50M derived: sum of 3 quarters · filed 2025-03-13 | -$1.00K 10-K · filed 2025-03-13 |
| 2022-09-30 | $2.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$17.00K derived: sum of 2 quarters · filed 2023-11-09 | $2.48M 10-Q · filed 2023-11-09 | $2.46M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | -$2.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$8.00K 10-Q · filed 2023-08-08 | -$36.00K derived: sum of 3 quarters · filed 2024-03-05 | -$36.00K derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $2.50M 10-Q · filed 2023-05-09 | $2.47M derived: sum of 2 quarters · filed 2024-03-05 | $2.47M derived: sum of 3 quarters · filed 2024-03-05 | -$28.00K derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | -$28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$28.00K derived: sum of 2 quarters · filed 2024-03-05 | -$2.53M derived: sum of 3 quarters · filed 2024-03-05 | -$28.00K 10-K · filed 2024-03-05 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$2.50M derived: sum of 2 quarters · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | |
| 2021-06-30 | -$2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $2.50M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-17 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-03-03 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $0.00 derived: sum of 2 quarters · filed 2021-02-26 | -$2.00K derived: sum of 3 quarters · filed 2021-02-26 | -$117.00K 10-K · filed 2021-02-26 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$2.00K derived: sum of 2 quarters · filed 2019-11-12 | -$117.00K 10-Q · filed 2019-11-12 | |
| 2018-06-30 | -$2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$117.00K 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | -$115.00K 10-Q · filed 2019-05-14 | |||
| 2017-12-31 | $117.00K 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |